S Pecorelli

Summary

Country: Italy

Publications

  1. ncbi request reprint Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205 7199, USA
    Gynecol Obstet Invest 56:28-34. 2003
  2. ncbi request reprint Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    BJOG 111:613-8. 2004
  3. pmc Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, UAMS Medical Center, 4301 West Markham, Little Rock, AR 72205 7199, USA
    Br J Cancer 90:1814-24. 2004
  4. doi request reprint History of the FIGO cancer staging system
    Franco Odicino
    Department of Obstetrics and Gynecology, Gynecologic Oncology, University of Brescia, Brescia, Italy
    Int J Gynaecol Obstet 101:205-10. 2008
  5. pmc Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
    S Pecorelli
    Department of Obstetrics and Gynecology, University of Brescia, Brescia, Italy
    Ann Oncol 21:759-65. 2010
  6. pmc Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence
    Renata A Tassi
    Division of Gynecologic Oncology, Department Materno Infantile e Tecnologie Biomediche, University of Brescia, Brescia, Italy
    BMC Cancer 9:253. 2009
  7. pmc Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer
    Emiliano Cocco
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA
    BMC Cancer 10:349. 2010
  8. ncbi request reprint Consolidation therapies revisited: weekly paclitaxel
    S Pecorelli
    Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Int J Gynecol Cancer 13:208-11. 2003
  9. ncbi request reprint Optimizing gemcitabine regimens in ovarian cancer
    Sergio Pecorelli
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Brescia, Italy
    Semin Oncol 33:S17-25. 2006
  10. ncbi request reprint Cervical cancer staging
    Sergio Pecorelli
    Division of Obstetrics and Gynecology, Department of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Cancer J 9:390-4. 2003

Collaborators

Detail Information

Publications47

  1. ncbi request reprint Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205 7199, USA
    Gynecol Obstet Invest 56:28-34. 2003
    ..Prospective randomized studies are strongly warranted to confirm this hypothesis...
  2. ncbi request reprint Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA
    BJOG 111:613-8. 2004
    ..To assess the expression of total gangliosides in primary ovarian cancer cell lines, ascitic fluid and plasma of advanced ovarian cancer patients...
  3. pmc Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, UAMS Medical Center, 4301 West Markham, Little Rock, AR 72205 7199, USA
    Br J Cancer 90:1814-24. 2004
    ..A therapeutic strategy targeting HER-2/neu may be beneficial in patients harbouring chemotherapy-resistant USPC...
  4. doi request reprint History of the FIGO cancer staging system
    Franco Odicino
    Department of Obstetrics and Gynecology, Gynecologic Oncology, University of Brescia, Brescia, Italy
    Int J Gynaecol Obstet 101:205-10. 2008
    ..This paper reviews the history of the International Federation of Gynecology and Obstetrics (FIGO) cancer staging system, how it was developed, and why...
  5. pmc Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
    S Pecorelli
    Department of Obstetrics and Gynecology, University of Brescia, Brescia, Italy
    Ann Oncol 21:759-65. 2010
    ..A prospective phase II study was conducted to evaluate the efficacy and toxicity of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer...
  6. pmc Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence
    Renata A Tassi
    Division of Gynecologic Oncology, Department Materno Infantile e Tecnologie Biomediche, University of Brescia, Brescia, Italy
    BMC Cancer 9:253. 2009
    ....
  7. pmc Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer
    Emiliano Cocco
    Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA
    BMC Cancer 10:349. 2010
    ..Using high-throughput technologies to analyze genetic fingerprints of ovarian cancer, we have discovered extremely high expression of the genes encoding the proteins claudin-3 and claudin-4...
  8. ncbi request reprint Consolidation therapies revisited: weekly paclitaxel
    S Pecorelli
    Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Int J Gynecol Cancer 13:208-11. 2003
    ..7% delay in treatment delivery. Therefore, weekly paclitaxel has been proven to be easily administered even in heavily pretreated patients, with acceptable hematological and neurological toxicity...
  9. ncbi request reprint Optimizing gemcitabine regimens in ovarian cancer
    Sergio Pecorelli
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Brescia, Italy
    Semin Oncol 33:S17-25. 2006
    ....
  10. ncbi request reprint Cervical cancer staging
    Sergio Pecorelli
    Division of Obstetrics and Gynecology, Department of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Cancer J 9:390-4. 2003
    ..However, surgical and pathological data are important for precise analysis of survival and prognostic risk factors...
  11. ncbi request reprint Mammaglobin B expression in human endometrial cancer
    R A Tassi
    Division of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Int J Gynecol Cancer 18:1090-6. 2008
    ..MGB-2 is highly expressed in EEC, particularly in well- and moderately differentiated tumors, and may represent a novel molecular marker for EEC...
  12. pmc Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas
    E Bignotti
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Brescia, Viale Europa 11, 25123 Brescia, Italy
    Br J Cancer 99:768-73. 2008
    ..Further investigations on a wider set of samples are warranted to validate TFF3 as a novel serum marker for early detection and/or monitoring of G3-EEC patients...
  13. doi request reprint Claudin-7 expression in human epithelial ovarian cancer
    R A Tassi
    Division of Gynecologic Oncology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy
    Int J Gynecol Cancer 18:1262-71. 2008
    ....
  14. ncbi request reprint Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205-7199, USA
    Gynecol Obstet Invest 51:254-61. 2001
    ....
  15. pmc Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Br J Cancer 92:1561-73. 2005
    ..Our results highlight the novel molecular features of USPC and provide a foundation for the development of new type-specific therapies against this highly aggressive variant of endometrial cancer...
  16. ncbi request reprint HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization
    F E Odicino
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Int J Gynecol Cancer 18:14-21. 2008
    ..The use of trastuzumab (Herceptin), a monoclonal antibody directed against HER-2/neu, for the therapy of patients with HER-2/neu-positive USPCs should be further investigated in clinical trials...
  17. ncbi request reprint Early stage ovarian cancer: the Italian contribution to clinical research. An update
    G Favalli
    Department of Gynecologic Oncology, Spedali Civili, University of Brescia, Brescia, Italy
    Int J Gynecol Cancer 11:12-9. 2001
    ..Results will probably be available during this year and are expected with a great interest by the whole scientific international community...
  18. pmc Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients
    E Bignotti
    Angelo Nocivelli Institute of Molecular Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Brescia, Viale Europa 11, 25123, Brescia, Italy
    Br J Cancer 104:1418-25. 2011
    ..The aims of this study were to investigate HE4 gene, protein expression and serum HE4 (sHE4) levels in a panel of ECs and normal endometria (NEs) and to correlate sHE4 with patient clinicopathological characteristics and prognosis...
  19. ncbi request reprint Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients
    E Sartori
    Department of Gynecology and Obstetrics, University of Brescia, Brescia, Italy
    Gynecol Oncol 107:S241-7. 2007
    ..The aim of this study was to evaluate the outcome benefit of follow-up protocols for patients with recurrent endometrial and cervical cancer...
  20. ncbi request reprint Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium
    S Pecorelli
    Department of Obstetrics and Gynaecology, University of Brescia, Italy
    Cancer Chemother Biol Response Modif 22:515-44. 2005
  21. ncbi request reprint Staging of gynecologic malignancies
    F Odicino
    Department of Obstetrics and Gynecology, University of Brescia, Italy
    Surg Clin North Am 81:753-70. 2001
    ..The rules for proper staging according to scientific evidence are presented in this article. Some of the most debatable issues are also discussed...
  22. ncbi request reprint Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer
    A D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, UAMS Medical Center, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Int J Gynecol Cancer 14:64-75. 2004
    ..DC-stimulated TIL may represent a superior source of tumor-specific CTL for adoptive T-cell immunotherapy for advanced ovarian cancer...
  23. ncbi request reprint Cancer in pregnancy: maternal and fetal implications on decision-making
    A Gambino
    Department Obstetrics and Gynecology, University of Brescia, Italy
    Eur J Gynaecol Oncol 32:40-5. 2011
    ..Cancer complicates one out of 1,000 pregnancies. No standardized therapeutic interventions have been reported for these patients...
  24. ncbi request reprint Systemic therapy for gynecological neoplasms: ovary, cervix and endometrium
    S Pecorelli
    Department of Obstetrics and Gynaecology, University of Brescia, Italy
    Cancer Chemother Biol Response Modif 21:565-84. 2003
    ..In a small subset of patients, who wish to have children, conservative treatment (hormonal therapy) could be considered. The most effective agents for palliation of advanced disease are doxorubicin plus cisplatin...
  25. ncbi request reprint Cancer in women
    S Pecorelli
    Department of Gynaecology and Obstetrics, Gynecologic Oncology, Spedali Civili, University of Brescia, Brescia, Italy
    Int J Gynaecol Obstet 82:369-79. 2003
    ..These effects were not detected in the less developed areas because of the limited access to primary and specialist care...
  26. ncbi request reprint Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients
    A Ravaggi
    Division of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Arch Virol 151:1899-916. 2006
    ....
  27. ncbi request reprint Ataxia-telangiectasia and endodermal sinus tumor of the ovary: report of a case
    S Pecorelli
    Department of Obstetrics and Gynecology, University of Brescia, Spedali Civili, Italy
    Gynecol Oncol 29:240-4. 1988
    ..This case report serves to focus on the particular problems encountered in the diagnosis and management of two diseases both characterized by the same serum marker...
  28. ncbi request reprint International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma
    J Baptist Trimbos
    Department of Gynecology, Leiden University Medical Center, The Netherlands
    J Natl Cancer Inst 95:105-12. 2003
    ..Adjuvant chemotherapy has been suggested as a possible strategy to improve survival in women with early-stage ovarian cancer; however, all randomized studies to date have been too small to answer this question reliably...
  29. ncbi request reprint Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial
    J Baptist Trimbos
    Leiden University Medical Center, Leiden, The Netherlands
    J Natl Cancer Inst 95:113-25. 2003
    ..We performed a prospective unblinded, randomized phase III trial to test the efficacy of adjuvant chemotherapy in patients with early-stage ovarian cancer, with emphasis on the extent of surgical staging...
  30. ncbi request reprint Current treatment options for endometrial cancer
    Alessandro D Santin
    University of Arkansas for Medical Sciences, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, 4301 West Markham Street, Slot 518, Little Rock, AR 72205, USA
    Expert Rev Anticancer Ther 4:679-89. 2004
    ..Anti-HER-2/neu-targeted therapy might be a novel and attractive therapeutic strategy in patients harboring this biologically aggressive variant of endometrial cancer...
  31. ncbi request reprint Early stage cervical cancer: adjuvant treatment in negative lymph node cases
    Enrico Sartori
    Gynecologic Oncology Division of University of Brescia, Italy
    Gynecol Oncol 107:S170-4. 2007
    ..In this retrospective study, we analyze the role of adjuvant radiotherapy in negative node patients and the possibility of this treatment to improve survival in selected groups...
  32. ncbi request reprint Overexpression of HER-2/neu in uterine serous papillary cancer
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas, Little Rock 72205 7199, USA
    Clin Cancer Res 8:1271-9. 2002
    ..In this study, we have evaluated the expression of HER-2/neu in several fresh, established, paraffin-embedded, fixed USPCs. In addition, we have tested the sensitivity of USPC cells to Herceptin treatment...
  33. ncbi request reprint Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women
    Andrea Decensi
    Division of Chemoprevention, European Institute of Oncology, Milan, Italy
    Circulation 106:1224-8. 2002
    ..Because the effect of transdermal estradiol (E2) on CRP is unclear, we compared CRP changes after 6 and 12 months of transdermal E2 and oral CEE in a randomized 2x2 retinoid-placebo trial...
  34. ncbi request reprint Interval debulking surgery in advanced epithelial ovarian cancer
    Sergio Pecorelli
    Department of Obstetrics and Gynaecology, Division of Gynaecological Oncology, University of Brescia, Spedali Civili di Brescia, Italy
    Best Pract Res Clin Obstet Gynaecol 16:573-83. 2002
    ....
  35. ncbi request reprint Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Cancer 104:1391-7. 2005
    ..In the current study, the authors have determined the frequency and clinical significance of HER-2/neu gene amplification in uterine serous papillary endometrial carcinoma (USPC), a highly aggressive variant of endometrial carcinoma...
  36. ncbi request reprint HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, 4301 W Markham, Little Rock, AR 72205 7199, USA
    Gynecol Oncol 100:469-78. 2006
    ....
  37. ncbi request reprint High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer
    Stefania Bellone
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Gynecol Oncol 98:92-8. 2005
    ....
  38. doi request reprint Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Yale University School of Medicine, New Haven, Connecticut 06520 8063, USA
    Int J Gynaecol Obstet 102:128-31. 2008
    ..To study the effect of trastuzumab in patients with progressive or recurrent metastatic endometrial carcinoma shown by immunohistochemistry to overexpress the HER2/neu receptor...
  39. ncbi request reprint The Italian gynecological consensus statement on the use of epoetin alfa in the management of anemia
    Sergio Pecorelli
    Department of Gynecologic Oncology, Universita degli Studi di Brescia, Italy
    Semin Oncol 29:13-5. 2002
    ....
  40. pmc Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial
    Alessandro D Santin
    UAMS Medical Center, Division of Gynecologic Oncology, University of Arkansas, 4301 W Markham, Little Rock, AR 72205 7199, USA
    J Virol 82:1968-79. 2008
    ..Phase II E7-pulsed DC-based vaccination trials with cervical cancer patients harboring a limited tumor burden, or who are at significant risk of tumor recurrence, are warranted...
  41. ncbi request reprint Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 7199, USA
    Cancer Res 65:4334-42. 2005
    ..e., 4-week established OVA-1). Our findings suggest that CPE may have potential as a novel treatment for chemotherapy-resistant/recurrent ovarian cancer...
  42. ncbi request reprint Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy
    Eliana Bignotti
    Division of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Gynecol Oncol 103:405-16. 2006
    ..To compare the genetic fingerprints of flash-frozen ovarian serous carcinomas to those of matched highly purified primary tumor cell cultures...
  43. ncbi request reprint Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease
    Stefania Bellone
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Gynecol Oncol 106:513-20. 2007
    ..To evaluate the sensitivity of cervical cancer cell lines to treatment with a chimeric MAb against EGFR-1 (Cetuximab)...
  44. ncbi request reprint Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy
    Alessandro D Santin
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, AR 72205 7199, USA
    Int J Cancer 112:14-25. 2004
    ..NOVA. These results, obtained with highly purified primary cultures of ovarian cancer, highlight important molecular features of OSPC and may provide a foundation for the development of new type-specific therapies against this disease...
  45. ncbi request reprint Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes
    Eliana Bignotti
    Division of Gynecologic Oncology, University of Brescia Medical School, Brescia, Italy
    Am J Obstet Gynecol 196:245.e1-11. 2007
    ..The purpose of this study was to identify genes that are highly differentially expressed in metastatic serous papillary ovarian tumors (MET) when compared with primary ovarian serous carcinomas (OSPC)...
  46. ncbi request reprint Overexpression of mammaglobin B in epithelial ovarian carcinomas
    Renata A Tassi
    Division of Gynecologic Oncology, University of Brescia, Brescia, Italy
    Gynecol Oncol 105:578-85. 2007
    ..In order to evaluate its potential as a novel ovarian cancer biomarker, in this study we quantified and compared Mammaglobin B expression in various histologic types of epithelial ovarian carcinomas (EOC)...
  47. ncbi request reprint Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization
    Alessandro D Santin
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Arkansas for Medical Sciences, 4301 W Markham Street, Slot 518, Little Rock, AR 72205 7199, USA
    Gynecol Oncol 98:24-30. 2005
    ..To evaluate and compare HER2/neu protein overexpression and gene amplification in uterine serous papillary endometrial cancer (USPC)...